The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes

Blood

Volumn 107, Issue 4, 2006, Pages 1476-1483

  Sun, Yuansheng ^a   Stevanović, Stefan ^b   Song, Mingxia ^b   Schwantes, Astrid ^b   Kirkpatrick, C James ^b   Schadendorf, Dirk ^b   Cichutek, Klaus ^b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; MATRIGEL; PEPTIDE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ADOPTIVE IMMUNOTHERAPY; ALGORITHM; AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOASSAY; INFLAMMATION; MOLECULAR CLONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; SENSITIZATION; STEM CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VASCULAR ENDOTHELIUM;

EID: 32644448585     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-1912     Document Type: Article

References (43)

1. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe OW, Pollock RE, Weichselbaum RR, eds. Cancer Medicine. Hamilton, ON, Canada: DC Decker; 2000:132-152.
2. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83-90.
3. Kerbel R, Kolkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
4. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8:1369-1375.
5. Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002;195:1575-1584.
6. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 2003;102:964-971.
7. Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000;6:1160-1166.
8. Pan J, Heiser A, Marget M, Steinmann J, Kabelitz D. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Ther. 2005;12:742-750.
9. Tan GH, Wie YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol. 2004;34:2012-2021.
10. Liu JY, Wie YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003;102:1815-1823.
11. Li Y, Bohlen P, Hicklin DJ. Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med. 2003;3:773-779.
12. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401-411.
13. Celis E, Fikes J, Wentworth P, et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 1994;31:1423-1430.
14. Riley JP, Rosenberg SA, Parkhurst MR. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities. J Immunol Methods. 2003;276:103-119.
15. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
16. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255-1262.
17. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21:505-515.
18. Boyer SJ. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr Top Med Chem. 2002;2:973-1000.
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
20. Sun Y, Song M, Stevanovic S, et al. Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000;87:399-404.
21. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545-586.
22. Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA-AA*0201 epitope identified by mass spectrometry. Cancer Res. 2001;61:4072-4077.
23. Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther. 2005;12:900-912.
24. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther. 2001;12:921-932.
25. Syfpeithi: a database of MHC ligands and peptide motifs (ver. 1.0). http://www.syfpeithi.de. Accessed March 26, 2003.
26. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.
27. Sun Y, Sijts AJ, Song M, et al. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res. 2002;62:2875-2882.
28. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
29. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
30. Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T lymphocyte-endothelial cell interactions. Annu Rev Immunol. 2004;22:683-709.
31. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem. 1998;273:22128-22135.
32. De Cesaris P, Starace D, Starace G, Filippini A, Stefanini M, Ziparo E. Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression. J Biol Chem. 1999;274:28978-28982.
33. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med. 2004;350:1461-1463.
34. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
35. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
36. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metast Rev. 1998;17:155-161.
37. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209-5218.
38. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
39. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol. 1995;164:385-394.
40. Ziegler BL, Valtieri M, Porada GA, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999;285:1553-1558.
41. + cells from cord blood. Stem Cells. 2001;19:24-36.
42. Folkman J. Angiogenesis inhibitors. Cancer Biol Ther. 2003;2(suppl 1):S127-S133.
43. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol. 2001;19:45s-51s.